Showing results (211-220 of 223) with videos related to
Sort By:
Pageof 23
European Journal of Cancer (Oxford, England : 1990)|February 16, 2023
Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trialYungan Tao, Xu-Shan Sun, Yoann Pointreau, et al.Molecular Oncology|April 10, 2022
Human papilloma virus integration sites and genomic signatures in head and neck squamous cell carcinomaJuliette Mainguené, Sophie Vacher, Maud Kamal, et al.Nature|May 31, 2023
In situ tumour arrays reveal early environmental control of cancer immunityGuadalupe Ortiz-Muñoz, Markus Brown, Catherine B Carbone, et al.The Lancet. Oncology|April 1, 2020
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trialJosé Trigo, Vivek Subbiah, Benjamin Besse, et al.Nature Communications|March 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human studyYonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist, et al.Nature|August 2, 2023
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancerPhilippe A Cassier, Raul Navaridas, Melanie Bellina, et al.Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatmentVivek Subbiah, Luis Paz-Ares, Benjamin Besse, et al.Cancer Discovery|June 1, 2018
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 AlterationsSumanta K Pal, Jonathan E Rosenberg, Jean H Hoffman-Censits, et al.Journal of Experimental & Clinical Cancer Research : CR|June 2, 2022
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumorsStephen L Chan, Martin Schuler, Yoon-Koo Kang, et al.Nature Cancer|June 30, 2025
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trialEdith Borcoman, Bastien Cabarrou, Miguel Francisco, et al.Pageof 23